Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein
June 28, 2023 03:30 ET
|
Philogen
Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein Siena, Italy, 28th June 2023 – Philogen S.p.A (BIT: PHIL) today announced that it has...
Philogen Announces Clinical Trial Collaboration with MSD
June 01, 2023 02:30 ET
|
Philogen
The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and...
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand
May 30, 2023 01:00 ET
|
Philogen
Mumbai, India and Siena, Italy, 30th May 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or...
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich
May 25, 2023 02:00 ET
|
Philogen
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich L19TNF (also known as Fibromun) is an...
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries
November 07, 2022 11:07 ET
|
Philogen
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries The study highlights the application of DNA-Encoded Chemical...
Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma
July 25, 2022 08:00 ET
|
Philogen
Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma 214 patients recruited in the study, in line with...
PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS
November 24, 2021 03:00 ET
|
Philogen
PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS Siena, Italy, November 24, 2021 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody...
Philogen Provides Corporate Update
November 12, 2021 02:00 ET
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun are on track with planned timelines in pivotal clinical trialsFibromun shows potent activity in last-line glioblastoma in combination with...
Philogen Provides Corporate Update
September 29, 2021 04:58 ET
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress
May 12, 2021 13:00 ET
|
Philogen
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress May 12, 2021 NidlegyTM on track for Phase III European trial in stage IIIB/C melanoma. Opening of additional...